Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an...
...amyloid; PET = positron emission topography imaging of amyloid plaques using radiolabeled contrast agents; (A) Elan Corp. plc... ...Product Target Trial Data reported Population Pts Duration Cognition result Amyloid result Amyloid measure Completed? Elan Corp. plc... ...to the compound, the target or the trial design. The first big failure came from Elan Corp. plc...
Mereo BioPharma Group plc (LSE:MPH) announced a merger with OncoMed Pharmaceuticals Inc. (NASDAQ:OMED); the resulting entity will focus on development of Mereo's orphan disease pipeline and will be listed on London Stock Exchange and NASDAQ....
Cold Spring Harbor Laboratory researchers and a team from two Italian institutions have published two different strategies to fight immune-mediated lung metastases. Dormant cancer cells can persist for years before awakening and proliferating, leading to...
Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an...
...amyloid; PET = positron emission topography imaging of amyloid plaques using radiolabeled contrast agents; (A) Elan Corp. plc... ...Product Target Trial Data reported Population Pts Duration Cognition result Amyloid result Amyloid measure Completed? Elan Corp. plc... ...to the compound, the target or the trial design. The first big failure came from Elan Corp. plc...
Mereo BioPharma Group plc (LSE:MPH) announced a merger with OncoMed Pharmaceuticals Inc. (NASDAQ:OMED); the resulting entity will focus on development of Mereo's orphan disease pipeline and will be listed on London Stock Exchange and NASDAQ....
Cold Spring Harbor Laboratory researchers and a team from two Italian institutions have published two different strategies to fight immune-mediated lung metastases. Dormant cancer cells can persist for years before awakening and proliferating, leading to...
Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...